Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Allergic Rhinitis
Interventions: Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge; Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type I Hypersensitivity
Interventions: TreeMATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 10
States / cities: Mission Viejo, California • San Jose, California • Woodstock, Georgia + 7 more

Conditions: Perennial Allergic Rhinitis
Interventions: Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Cetirizine, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Allergic Conjunctivitis to Tree Pollen or Grass Pollen
Interventions: Fluticasone furoate nasal spray, Placebo nasal spray; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Orotic acid and Glutathione-(Nutritional Supplements); Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Seasonal Allergic Rhinitis
Interventions: Vitamin D3, Placebo, Fluticasone Propionate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine Hydrochloride Nasal Spray 0.6%, Vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 2,388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Kenilworth, Illinois

Conditions: Allergy Pollen
Interventions: Spiriplex Allergenex Microassay; Diagnostic Test
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose, placebo comparator nasal product; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Irvine, California

Conditions: Rhinitis, Allergic, Seasonal
Interventions: C-1266-7, C-1266-6 (placebo); Device
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GSP 301 Placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 32
States / cities: Mission Viejo, California • Ontario, California • Paramount, California + 26 more

Conditions: Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions: Bilastine, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Immunologic Desensitization
Interventions: allergen extract tablet, Placebo tablet; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

Vitamin D Plus Fluticasone Propionate

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

Microassay and Allergy Skin Prick Test Correlation Study

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy